Round Hill Asset Management Maintains Stake in Bristol-Myers Squibb Company (BMY)

Round Hill Asset Management maintained its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,895 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Round Hill Asset Management’s holdings in Bristol-Myers Squibb were worth $663,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC grew its stake in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. American National Bank lifted its holdings in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares during the period. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. BDO Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb in the second quarter valued at approximately $123,000. Finally, Proficio Capital Partners LLC lifted its holdings in Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares during the period. 69.82% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.02 on Wednesday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The firm has a market cap of $102,244.66, a price-to-earnings ratio of 21.10, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $0.77 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

Several equities analysts recently weighed in on the stock. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Goldman Sachs Group restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Jefferies Group restated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Finally, Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $64.93.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Round Hill Asset Management Maintains Stake in Bristol-Myers Squibb Company (BMY)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/06/round-hill-asset-management-maintains-stake-in-bristol-myers-squibb-company-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit